Sector News

Novo Nordisk and Novartis put Victoza patent suit to bed, teeing up Sandoz copycat by 2024

March 27, 2022
Life sciences

After Teva Pharmaceutical snagged the OK to launch its Victoza generic in 2023, another copycat has secured a launch timeline for its generic to Novo Nordisk’s aging GLP-1 mainstay.

Novo Nordisk and Novartis’ Sandoz have settled a patent infringement lawsuit covering the Danish drugmaker’s diabetes blockbuster Victoza, according to court documents filed Tuesday in the U.S. District Court for the District of Delaware.

The companies reached an accord shortly before an April trial in Delaware federal court, Bloomberg Law first pointed out.

Under the agreement, Sandoz is cleared to launch its generic version of Victoza by June 22, 2024—or “earlier under certain circumstances,” a Novo Nordisk spokesperson told Fierce Pharma.

“This settlement reflects the comprehensive US patent portfolio for liraglutide,” Tomas Haagen, group general counsel and senior vice president of Novo Nordisk, added in the company’s emailed statement. “Novo Nordisk will continue to defend our broad intellectual property portfolio for innovative drugs against challenges,” he said.

Back in 2021, Moody’s analysts estimated Victoza’s patent protection would run out between 2022 and 2023, which lines up with Novo’s own word. Victoza’s active ingredient patent is set to lapse in the U.S. and Europe in 2023, the company said (PDF) in its 2021 annual report. Victoza’s active ingredient patent will expire in Japan in 2022, and it’s already run out in China, the company has noted.

Aside from Sandoz, generics juggernauts Teva Pharmaceutical and Viatris—formerly Mylan—also have Victoza copycats lined up. Novo in 2019 settled a patent dispute with Teva, keeping the Israeli-American pharma’s generic at bay until late 2023.

At the time, Novo pointed out that Teva’s prospective launch date would be delayed by six months, provided Novo scored pediatric exclusivity for Victoza. That same year, Victoza snagged an FDA label expansion to include kids and teens ages 10 to 17 with Type 2 diabetes.

That pediatric green light could delay Teva’s entry until early 2024, around the same time that Novartis’ copycat is due to grace the stage.

Meanwhile, in 2020, Mylan contested Victoza patent No. 8,114,833, covering the med’s manufacturing and formulation, which protects Novo’s diabetes drug through early 2026.

The companies had settled as of April 2021, according to online legal repository JD Supra, though it’s unclear exactly when Viatris’ generic will debut.

A Novo Nordisk spokesperson said the company couldn’t provide further color on the Victoza settlement landscape at this time.

Victoza generated 15 billion Danish krone ($2.2 billion) in 2021, Novo reported (PDF) in February. The drug now fits into the company’s wider GLP-1 repertoire comprising diabetes med Ozempic, its oral counterpart Rybelsus and obesity newcomer and blockbuster-in-waiting Wegovy.

Novo’s sales of GLP-1 meds for Type 2 diabetes jumped 32% at constant exchange rates last year to 53.6 billion Danish krone ($7.9 billion).

By Fraiser Kansteiner


comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.